Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors

HRTX 11.04.2024

Full Press ReleaseSEC FilingsOur HRTX Tweets

About Gravity Analytica

Recent News

  • 12.23.2024 - Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina
  • 12.03.2024 - U.S. District Court Upholds Validity of CINVANTI® Patents
  • 11.12.2024 - Heron Therapeutics Q3 2024 Conference Call

Recent Filings

  • 01.22.2025 - 4 Statement of changes in beneficial ownership of securities
  • 12.23.2024 - 8-K Current report
  • 12.23.2024 - EX-99.1 EX-99.1

SAN DIEGO,Nov. 4, 2024/PRNewswire/ --Heron Therapeutics, Inc.(Nasdaq: HRTX), a commercial-stage biotechnology company, announced today the appointment ofMichael Kasetato its Board of Directors.Mr. Kasetahas an extensive background spanning corporate finance, business strategy, and the commercialization of biopharma products in large pharmaceutical companies and small biotech companies.

Mr. Kasetacurrently serves as the Chief Financial Officer and Chief Operating Officer of Liquidia Corporation, a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases. Prior to Liquidia,Mr. Kasetaserved as the Chief Financial Officer atAerami Therapeutics, Inc., a private biotech company focused on the development of improved therapies for the treatment of severe respiratory diseases, including pulmonary arterial hypertension. Previously,Mr. Kasetaserved as the Chief Financial Officer atAralez Pharmaceuticals, Inc., and spent eleven years atSanofi S.A.in a variety of financial roles, culminating in the Chief Financial Officer role atSanofi North America,Global Services. In this role he managed a$10 billionbusiness covering several product launches and more than 100 products across eight therapeutic areas.Mr. Kasetaholds a BBA in accounting fromJames Madison University, is a CPA (inactive) licensed in the state ofNew Jersey, and serves as a director of Bryn Pharma.

"We are excited to welcome Mike and his deep experience in commercial biotechnology leadership to Heron's Board of Directors," saidCraig Collard, Chief Executive Officer of Heron. "I look forward to working with Mike more closely and I am confident that he will be an important asset to the Board as we drive continued growth of our existing portfolio of proprietary products focused on improving the lives of patients."

About Heron Therapeutics, Inc.

Heron Therapeutics, Inc.is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visitwww.herontx.com.

Forward-looking Statements

This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the company's filings with theSecurities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.

Investor Relations and Media Contact:

Ira DuarteExecutive Vice President, Chief Financial OfficerHeron Therapeutics, Inc.iduarte@herontx.com858-251-4400

(PRNewsfoto/Heron Therapeutics, Inc.)

CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/heron-therapeutics-announces-appointment-of-michael-kaseta-to-board-of-directors-302295904.html

SOURCEHeron Therapeutics, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com